CME Group Inc.

NasdaqGS:CME Stock Report

Market Cap: US$99.1b

CME Group Future Growth

Future criteria checks 0/6

CME Group is forecast to grow earnings and revenue by 3.4% and 5.1% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be 17.8% in 3 years.

Key information

3.4%

Earnings growth rate

5.13%

EPS growth rate

Capital Markets earnings growth11.8%
Revenue growth rate5.1%
Future return on equity17.81%
Analyst coverage

Good

Last updated11 Sep 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Aug 25

CME Group: The Price Stands Still, But The Growth Engines Accelerate

Summary CME Group remains a Buy, driven by robust volumes, an expanding fixed-income ecosystem, and product innovation, despite a full valuation. CME's Q2 2026 saw record revenues, strong margins near 70%, and notable growth in international and retail trading volumes. Key catalysts include Treasury Link integration, 24/7 trading, Compute futures, and regulatory tailwinds in clearing requirements. Competition from perpetual futures and a premium valuation at 21x forward earnings temper near-term upside, but long-term growth and capital returns support the rating. Read the full article on Seeking Alpha
Narrative Update • Jul 28

CME: Perpetual Futures Dispute And New Contracts Will Shape Earnings Profile

The analyst fair value estimate for CME Group has been trimmed by about $6.64 to $282.36, as analysts balance slightly higher projected revenue growth with lower profit margin assumptions and a modestly reduced future P/E multiple following a mix of recent target cuts and increases across the Street. Analyst Commentary Recent research on CME Group shows a split view, with some firms lifting price targets and ratings while others trim expectations and flag competitive threats.
Narrative Update • Jul 09

CME: Crypto Perpetual Futures Dispute Will Reshape Long Term Earnings Power

The analyst price target for CME Group has been trimmed by about $14 to reflect slightly softer revenue growth assumptions, a modestly higher discount rate, and lower future P/E multiples that many analysts link to competitive concerns around perpetual futures, despite broadly constructive views on the core franchise. Analyst Commentary Recent research on CME Group highlights a split view, with some analysts seeing attractive upside after the share pullback and others focusing on competitive threats and pricing pressure.
Narrative Update • Jun 24

CME: Crypto Perpetual Futures Dispute Will Shape Future Earnings Power

The analyst price target for CME Group has shifted slightly lower, with fair value moving from about $306.47 to $302.60 as analysts weigh ongoing concerns around perpetual futures and potential multiple compression against views that recent share weakness and structural demand drivers still support an attractive long term setup. Analyst Commentary Recent research on CME Group shows a split between bullish analysts who see the recent pullback and product portfolio as supportive for long term value, and more cautious voices focused on competitive threats from perpetual futures and the potential impact on valuation multiples.
Analysis Article • Jun 18

CME Group (CME) Stock Could Be 18% Undervalued After CEO Succession News

CME Group (CME) stock is in focus after the company confirmed a leadership transition that will see long time Chairman and CEO Terry Duffy move to Executive Chairman while President and CFO Lynne Fitzpatrick becomes CEO in 2027. See our latest analysis for CME Group. The leadership announcement landed against a weaker backdrop for CME Group stock, with the share price down 3.46% over the past day and 17.23% over the past 30 days, while the 5 year total shareholder return of 45.07% still...
Narrative Update • Jun 05

CME: Crypto And AI Futures Expansion Will Shape Future Earnings Power

Analysts have trimmed their average price target for CME Group to about $306.47. This reflects concerns that revenue momentum could soften as geopolitical volatility eases and that fresh competition in bitcoin perpetual futures may weigh on exchange valuations, even as several firms still see the competitive risk as manageable.
Narrative Update • May 15

CME: Mixed Street Views And New Markets Will Shape Future Earnings Power

Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.
Narrative Update • Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Narrative Update • Apr 11

CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes

The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.
Narrative Update • Mar 26

CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix

Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.
Narrative Update • Mar 11

CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook

Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.
Narrative Update • Feb 25

CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook

The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.
Narrative Update • Feb 10

CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook

The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.
Narrative Update • Jan 27

CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook

The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.
Narrative Update • Jan 12

CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook

Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.
Narrative Update • Dec 27

CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks

Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.
Narrative Update • Dec 13

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.
Narrative Update • Nov 16

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.

Earnings and Revenue Growth Forecasts

NasdaqGS:CME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287,7874,5135,1845,3427
12/31/20277,3544,4254,8785,03413
12/31/20267,0264,3894,3704,81013
6/30/20266,7574,2654,2134,309N/A
3/31/20266,7444,2354,3294,420N/A
12/31/20256,5074,0214,1944,277N/A
9/30/20256,3853,7174,0844,161N/A
6/30/20256,4333,7214,1074,196N/A
3/31/20256,2743,5813,8263,914N/A
12/31/20246,1203,4823,5973,691N/A
9/30/20246,0343,4223,6283,717N/A
6/30/20245,7883,2623,4923,571N/A
3/31/20245,6163,1573,3633,444N/A
12/31/20235,5793,1863,3773,454N/A
9/30/20235,3383,0113,3113,391N/A
6/30/20235,2282,9423,1083,192N/A
3/31/20235,1042,8283,0783,159N/A
12/31/20225,0192,6572,9663,056N/A
9/30/20224,8332,6332,6502,743N/A
6/30/20224,7152,8892,6162,717N/A
3/31/20224,6572,7452,4772,599N/A
12/31/20214,6902,6172,2752,402N/A
9/30/20214,6302,4352,2252,394N/A
6/30/20214,6001,9201,8882,074N/A
3/31/20214,6031,9132,3782,561N/A
12/31/20204,8842,1052,5182,716N/A
9/30/20204,9112,1512,5812,775N/A
6/30/20205,1092,3753,0713,274N/A
3/31/20205,2002,386N/A2,761N/A
12/31/20194,8682,117N/A2,673N/A
9/30/20194,9592,033N/A2,464N/A
6/30/20194,5881,808N/A2,236N/A
3/31/20194,3771,860N/A2,285N/A
12/31/20184,3091,962N/A2,441N/A
9/30/20183,9734,516N/A2,391N/A
6/30/20183,9594,413N/A2,316N/A
3/31/20183,8244,262N/A2,057N/A
12/31/20173,6454,063N/A1,751N/A
9/30/20173,6581,498N/A1,801N/A
6/30/20173,6091,662N/A1,773N/A
3/31/20173,5901,566N/A1,732N/A
12/31/20163,5951,534N/A1,732N/A
9/30/20163,4961,452N/A1,607N/A
6/30/20163,5051,340N/A1,591N/A
3/31/20163,4181,284N/A1,626N/A
12/31/20153,3271,247N/A1,533N/A
9/30/20153,3541,262N/A1,644N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CME's forecast earnings growth (3.4% per year) is below the savings rate (3.7%).

Earnings vs Market: CME's earnings (3.4% per year) are forecast to grow slower than the US market (17.2% per year).

High Growth Earnings: CME's earnings are forecast to grow, but not significantly.

Revenue vs Market: CME's revenue (5.1% per year) is forecast to grow slower than the US market (13.4% per year).

High Growth Revenue: CME's revenue (5.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CME's Return on Equity is forecast to be low in 3 years time (17.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 03:58
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CME Group Inc. is covered by 32 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephen BiggarArgus Research Company
Benjamin BudishBarclays
Roger FreemanBarclays